10-Q: Biofrontera Narrows 9-Month Loss, Completes Key Deals

Sentiment:

Quarterly Report 12 November 2025 4:31 PM

Biofrontera Inc. reported a narrowed nine-month net loss, completed a strategic acquisition of Ameluz rights, and sold its Xepi product line, while addressing Nasdaq compliance issues.

Delay expectedThe timing of the International Trade Commission's Final Determination regarding Sun's patent claims against the RhodoLED-XL, expected by February 2, 2026, may be impacted by a federal government shutdown that started on October 1, 2025.

Capital raiseThe company secured an $11 million investment from existing investors through a private placement of Series C Convertible Preferred Stock.The offering consisted of two tranches: $8.5 million closed on July 1, 2025, and the remaining $2.5 million was funded on October 24, 2025.

Worse than expectedNet loss for the three months ended September 30, 2025, widened to $6.649 million from $5.669 million in the prior year quarter.Product revenues decreased by 22.5% for the three months ended September 30, 2025, and by 0.6% for the nine months ended September 30, 2025.Cash flows used in operating activities increased to $10.985 million for the nine months ended September 30, 2025, from $9.253 million in the prior year period, indicating increased cash burn.The company's stockholders' equity shifted to a deficit of $2.581 million as of September 30, 2025, from a positive equity position at the end of 2024.The company explicitly states that factors raise substantial doubt about its ability to continue as a going concern.

Summary

Net loss for the nine months ended September 30, 2025, was $16.176 million, a slight improvement from $16.363 million in the prior year period.
Product revenues for the nine months ended September 30, 2025, decreased by 0.6% to $24.605 million compared to $24.744 million in the same period of 2024.
For the three months ended September 30, 2025, net loss widened to $6.649 million from $5.669 million in the prior year quarter, and product revenues decreased by 22.5% to $6.988 million.
The company completed a Strategic Transaction on October 20, 2025, acquiring all U.S. rights to Ameluz and RhodoLED from Biofrontera AG, replacing the previous transfer pricing model with an earnout structure (12% or 15% of Ameluz revenue).
The Strategic Transaction was funded by an $11 million investment from existing investors, with $8.5 million received in July 2025 and $2.5 million in October 2025.
Biofrontera AG received 3,019 shares of Series D Convertible Preferred Stock, representing a 10% post-money equity stake in the company, as part of the Strategic Transaction.
The Xepi product line was sold to Pelthos Therapeutics Inc. on November 6, 2025, for a maximum purchase price of $10.0 million, including $3.0 million cash at closing and potential earnouts.
The company regained compliance with Nasdaq's $1.00 bid price rule on November 6, 2025, and the stockholders' equity requirement on November 4, 2025, following the Strategic Transaction and capital raise.
Cash and cash equivalents decreased to $3.417 million as of September 30, 2025, from $5.905 million at December 31, 2024.
Cash flows used in operating activities increased to $10.985 million for the nine months ended September 30, 2025, from $9.253 million in the prior year period.
The accumulated deficit increased to $133.585 million as of September 30, 2025, from $117.409 million at December 31, 2024, and stockholders' equity shifted to a deficit of $2.581 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company has made significant strategic moves (Ameluz rights acquisition, Xepi sale) and regained Nasdaq compliance post-period, the underlying financial performance for the reported period shows widening losses, increased cash burn, and a shift to stockholders' deficit. The explicit 'going concern' warning and ongoing, material legal challenges contribute to a cautious outlook despite the strategic efforts to improve future prospects.

Positives

Regained compliance with Nasdaq's minimum bid price rule ($1.00 per share) on November 6, 2025.
Regained compliance with Nasdaq's stockholders' equity requirement ($2.5 million minimum) on November 4, 2025, with stockholders' equity exceeding $5 million post-Strategic Transaction.
The Strategic Transaction for Ameluz and RhodoLED U.S. rights is expected to reduce overall costs and accelerate the company's timeframe to reach break-even.
Successfully raised $11 million through the issuance of Series C Preferred Stock from existing investors.
Sale of the Xepi product line for a maximum of $10.0 million provides immediate cash ($3.0 million at closing) and potential future earnout payments.
Cost of revenues, related party, significantly decreased by 60.0% for the three months and 42.5% for the nine months ended September 30, 2025, due to a reduced cost structure under the Second A&R Ameluz LSA.

Negatives

Incurred a net loss of $6.649 million for the three months ended September 30, 2025, an increase from $5.669 million in the prior year quarter.
Cash and cash equivalents decreased to $3.417 million as of September 30, 2025, from $5.905 million at December 31, 2024.
Cash flows used in operating activities increased to $10.985 million for the nine months ended September 30, 2025, from $9.253 million in the prior year period.
Accumulated deficit increased to $133.585 million as of September 30, 2025, from $117.409 million at December 31, 2024.
Stockholders' equity shifted to a deficit of $2.581 million as of September 30, 2025, from a positive equity of $4.433 million at December 31, 2024.
Selling, general and administrative expenses increased by 19.3% ($1.6 million) for the three months and 14.2% ($3.6 million) for the nine months ended September 30, 2025, primarily due to increased legal costs related to patent claims.
Product revenues decreased by 22.5% for the three months and 0.6% for the nine months ended September 30, 2025, primarily due to decreased sales volume of Ameluz.

Risks

Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the report's issuance date due to significant losses and cash outflows from operations.
Ongoing legal proceedings with DUSA Pharmaceuticals, Inc. alleging breach of contract, Lanham Act violations, and unfair trade practices, with an inability to estimate potential material loss.
Ongoing patent infringement litigation with Sun Pharmaceutical Industries, Inc. regarding the RhodoLED-XL, where an Initial Determination found Sun Patents valid and infringement, with potential for a limited exclusion order and inability to estimate material loss.
Inability to obtain sufficient external financing on acceptable terms, which could force delays or reductions in commercialization efforts or R&D programs.
Potential for delisting from Nasdaq if ongoing compliance with stockholders' equity requirements is not maintained in future periodic reports.
Geopolitical uncertainty and tariffs, particularly on imports from Europe, may increase inflationary pressure and raise product costs, which may not be fully offset by pricing adjustments.
Seasonality of Ameluz sales, with historically higher revenues in the first and fourth quarters, could impact financial results in other periods.

Future Outlook

The company expects the Strategic Transaction, which grants full U.S. rights to Ameluz and RhodoLED, to reduce overall costs and accelerate its path to break-even. The full transfer of assets and personnel related to this transaction is anticipated by late fourth quarter of 2025 or early first quarter of 2026. Proceeds from the Xepi product line sale are expected to provide liquidity. Research and development efforts will continue to focus on Ameluz label expansion and improving RhodoLED Lamps. The company plans to address its going concern doubt by utilizing external financing options, including a short-term line of credit, in addition to the Xepi sale proceeds.

Management Comments

"The new structure reduces overall cost for the Company and is expected to accelerate the Company's timeframe to reach break-even."

Industry Context

Biofrontera operates in the biopharmaceutical sector, specifically focusing on dermatological conditions with its photodynamic therapy (PDT) products, Ameluz and RhodoLED. The strategic acquisition of full U.S. rights to Ameluz and RhodoLED reflects a move towards greater control over its core product's commercialization and cost structure, a common strategy for companies seeking to optimize profitability and market penetration. The divestiture of the Xepi product line indicates a focus on core competencies and a streamlining of the product portfolio. The ongoing legal challenges, particularly patent infringement claims, highlight the competitive and litigious nature of the pharmaceutical industry, especially concerning intellectual property for established and emerging therapies.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Board of Directors	NA	NA	NA	Biofrontera AG has the right to appoint one or two individuals to the Board of Directors based on its Series D Preferred Stock holding, but no appointments have been made through the filing date.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stock Classification	Series C and Series D Convertible Preferred Stock were reclassified from mezzanine equity to permanent equity on the consolidated balance sheets and statements of change in stockholders' equity.	2025-09-16	Reflects a change in accounting treatment following a Special Shareholder Meeting where holders became entitled to receive the same form of consideration upon a liquidation event, aligning with permanent equity criteria.
Board Appointment Rights	Biofrontera AG, as a holder of Series D Preferred Stock, has the right to appoint one or two individuals to the company's board of directors for three years following the Strategic Transaction, depending on board size.	2025-10-20	Potentially increases influence of Biofrontera AG on the company's governance and strategic direction.

Legal Proceedings

DUSA Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries LTD filed a complaint against Biofrontera alleging breach of contract, violation of the Lanham Act, and unfair trade practices related to Ameluz product promotion. Discovery is ongoing, and the company cannot estimate the possibility or range of material loss.
Sun Pharmaceutical Industries, Inc. filed two complaints against Biofrontera, Biofrontera AG, Biofrontera Pharma, and Biofrontera Bioscience, alleging that the RhodoLED-XL infringes two patents held by Sun. An Administrative Law Judge (ALJ) issued an Initial Determination finding Sun Patents valid and infringement. The ITC's Final Determination is expected by February 2, 2026. The company cannot estimate the possibility or range of material loss, but an adverse ruling could result in a limited exclusion order on the product. Biofrontera has also challenged the validity of Sun Patents at the United States Patent Trial and Appeal Board (PTAB), with one petition instituted and a decision expected by February 24, 2026, and another denied.

Related Party Transactions

The company completed a Strategic Transaction with Biofrontera AG and its subsidiaries (Biofrontera Group) on October 20, 2025, to acquire all U.S. rights to Ameluz and RhodoLED. This involved an earnout agreement and the issuance of 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG.
The company agreed to assume the defense and all associated costs for co-defendant Biofrontera Group in certain legal actions pending in the United States.
Amounts due and payable to Biofrontera Group as of September 30, 2025, were $2.0 million, down from $5.3 million at December 31, 2024.
Purchases of licensed products (Ameluz and RhodoLED Lamps) from Biofrontera Pharma GmbH were $2.7 million for the three months and $7.7 million for the nine months ended September 30, 2025.
Other expenses paid to Biofrontera Group for services like regulatory support and pharmacovigilance were $0.3 million for the three months and $0.5 million for the nine months ended September 30, 2025.

Stakeholder Impact

Shareholders: Potential for significant share price volatility due to ongoing litigation, going concern doubts, and the strategic shifts. Dilution from preferred stock conversions is a factor. Regained Nasdaq compliance reduces immediate delisting risk but continued monitoring is required.
Employees: Increased R&D expenses and assumption of clinical trial control could lead to new opportunities, but financial instability and potential delays in R&D programs could create uncertainty.
Customers (Dermatologists): The acquisition of Ameluz rights aims to improve cost management and potentially ensure product availability and support, but legal challenges could impact product access or perception.
Suppliers (Biofrontera Group): The Strategic Transaction alters the financial relationship, moving from a transfer pricing model to an earnout, and involves the issuance of Series D Preferred Stock, maintaining a significant relationship.
Creditors: The 'going concern' warning and accumulated deficit indicate elevated risk, though the recent capital raise and Xepi sale provide some liquidity. Convertible notes represent a significant liability.

Next Steps

Complete the full transfer of assets and personnel related to the Strategic Transaction by late fourth quarter of 2025 or early first quarter of 2026.
Monitor and address ongoing compliance with Nasdaq's stockholders' equity requirement upon filing the next periodic report.
Await the International Trade Commission's Final Determination regarding Sun's patent infringement claims, expected by February 2, 2026.
Await the PTAB's final written decision on the instituted inter partes review petition, expected on or before February 24, 2026.
Commence the new office lease at 660 Main Street, Woburn, MA, on December 1, 2025.
Pursue external financing options, including a short-term line of credit, to address going concern doubts.
Work towards achieving milestone events for Xepi annual net sales to receive earnout consideration (initial $3.0 million upon $10.0 million sales, another $3.0 million upon $15.0 million sales).

Key Dates

Date	Description
2022-05-16	Original issuance date of 2022 Purchase Warrants.
2022-07-26	Original issuance date of 2022 Inducement Warrants.
2022-12-02	Entered into technology transfer agreement with Optical Tools LLC.
2023-05-28	Authorized Optical Tools to design, develop, manufacture, and deliver PDT Device prototypes.
2023-09-13	Served with a complaint filed by DUSA Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries LTD.
2023-11-02	Expiration date of 2022 Purchase Warrants and 2022 Inducement Warrants extended to November 2, 2028, and exercise price revised to $3.55 per share. Also, issuance date of 2023 Purchase Warrants.
2024-02-13	Effective date of the Second A&R Ameluz LSA, which reduced the transfer price.
2024-02-19	Entered into a securities purchase agreement for the issuance of Series B-1 Convertible Preferred Stock and warrants to purchase Series B-3 Convertible Preferred Stock.
2024-03-01	Biofrontera Company filed a partial motion to dismiss the Lanham Act and Massachusetts statutory claims in the DUSA complaint.
2024-06-01	Assumed control of all clinical trials relating to Ameluz in the United States.
2024-06-12	Stockholders approved an amendment to the 2021 Omnibus Incentive Plan to increase authorized shares.
2024-06-26	Sun filed a complaint against Biofrontera regarding RhodoLED-XL patent infringement in the Massachusetts District Court.
2024-06-27	Sun filed a complaint against Biofrontera regarding RhodoLED-XL patent infringement with the International Trade Commission (ITC).
2024-10-15	Motion to dismiss Lanham Act and Massachusetts statutory claims in DUSA case was denied.
2024-10-30	Biofrontera answered Sun's complaint and filed counterclaims.
2024-11-21	Entered into a securities purchase agreement for the issuance of Senior Secured Convertible Notes.
2024-11-22	Issued $4.2 million in aggregate principal amount of 10.0% Senior Secured Convertible Notes, maturing on November 22, 2027.
2024-12-17	Sun answered Biofrontera's counterclaims.
2025-02-24	PTAB instituted inter partes review for one of the Sun Patents.
2025-03-11	Received an additional notice from Sun alleging breach of contract through unlawful marketing practices.
2025-05-08	Received a letter from Nasdaq notifying non-compliance with the $1.00 bid price rule.
2025-05-21	Received a notice from Nasdaq notifying non-compliance with the stockholders' equity requirement ($2.5 million minimum).
2025-06-16	Filed Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation.
2025-06-30	Signed a binding Term Sheet with Biofrontera Group to acquire U.S. rights to Ameluz and RhodoLED. Also, filed Certificate of Designation for Series D Convertible Preferred Stock. Hearing held before an administrative law judge (ALJ) for the ITC case.
2025-07-01	First tranche of 8,500 Series C Preferred Shares closed, generating $8.5 million.
2025-07-02	PTAB issued a discretionary denial for inter partes review of another Sun Patent. Series D Preferred Stock issued to Biofrontera Group.
2025-07-24	Granted an extension by Nasdaq to regain compliance with the stockholders' equity rule on or before October 24, 2025.
2025-07-30	Entered into an agreement to lease new office space at 660 Main Street, Woburn, MA.
2025-09-16	Special Shareholder Meeting, after which Series C and D Preferred Stock were reclassified as permanent equity.
2025-09-30	End of the current reporting period. ALJ issued an Initial Determination finding Sun Patents valid and infringement in the ITC case.
2025-10-20	Strategic Transaction with Biofrontera AG finalized, executing Asset Purchase Agreement and Earnout Agreement.
2025-10-24	Second tranche of 2,500 Series C Preferred Shares funded, generating $2.5 million. Current Report on Form 8-K filed with Nasdaq.
2025-11-04	Received notice from Nasdaq confirming compliance with the stockholders' equity requirement.
2025-11-05	Deadline to regain Nasdaq bid price compliance. Nasdaq notified the company that it had regained compliance with the $1.00 bid price rule.
2025-11-06	Closed the Asset Purchase Agreement with Pelthos Therapeutics Inc. for the sale of the Xepi product line.
2025-11-10	Date of common stock outstanding count (11,648,323 shares).
2025-11-12	Date of filing of this Quarterly Report on Form 10-Q.
2025-12-01	Scheduled commencement date for the new office lease.
2026-02-02	Expected date for the ITC Final Determination regarding Sun's patent claims.
2026-02-24	Expected date for PTAB's final written decision on the instituted petition.
2027-11-22	Maturity date for the 10.0% Senior Secured Convertible Notes.
2028-08-01	Varying expiration dates for vehicle leases through August 2028.
2028-11-02	Expiration date for 2022 Purchase Warrants, 2022 Inducement Warrants, and 2023 Purchase Warrants.

Recommendation

hold

The company is in a significant transition phase, marked by the strategic acquisition of Ameluz U.S. rights and the divestiture of the Xepi product line, both of which are positive steps towards streamlining operations and improving the cost structure. The successful capital raise and regaining of Nasdaq compliance are also favorable. However, these positives are balanced by persistent operational losses, increased cash burn, a substantial accumulated deficit, and an explicit 'going concern' warning. Furthermore, the company faces material ongoing legal challenges that could have a significant adverse impact. Given this mixed bag of strategic progress against fundamental financial and legal uncertainties, a 'hold' recommendation is appropriate for seasoned investors to observe the execution of the new strategy and the resolution of legal matters before making further commitments.

Keywords

Biofrontera, BFRI, Ameluz, RhodoLED, Photodynamic Therapy, PDT, Actinic Keratoses, Dermatology, Biopharmaceutical, SEC Filing, 10-Q, Nasdaq Compliance, Xepi, Asset Sale, Strategic Transaction, Preferred Stock, Convertible Notes, Going Concern, Litigation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.